Company profile
SAGIMET BIOSCIENCES INC.
NASDAQ:SGMTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DENIFANSTAT | phase3 | — | 8 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07216313 | phase1 | completed | 2025-09-30 | 2025-10-20 | Sagimet Biosciences Inc. | A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants |
| NCT02223247 | phase1 | completed | 2013-11-01 | 2017-06-01 | Sagimet Biosciences Inc. | A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors |
| NCT06594523 | phase3 | withdrawn | 2025-03-01 | 2030-12-01 | Sagimet Biosciences Inc. | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis |
| NCT06692283 | phase3 | withdrawn | 2025-03-01 | 2026-06-01 | Sagimet Biosciences Inc. | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH |
| NCT05835180 | phase1 | completed | 2023-05-01 | 2023-12-18 | Sagimet Biosciences Inc. | A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function |
FDA applications (0)
No records yet.